Progress report on chlorambucil therapy in postsplenectomy patients with progressive hairy cell leukemia.
Of eight patients with progressive hairy cell leukemia who were treated with daily doses of an alkylating agent (chlorambucil, 4 mg) for at least 6 mo, seven have had an objective response, as measured by improved blood counts. Two patients were pancytopenic and had almost total bone marrow replacement with hairy cells at the initiation of chemotherapy; approximatley 6 mo later, their blood counts and bone marrow had improved dramatically. The five other patients had the leukemic form of the disease, and all responded to therapy. It is important to identify postsplenectomy patients with progressive disease in order to initiate low-dose single-agent chemotherapy.
D000493:Allopurinol / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D001856:Bone Marrow Examination; D002699:Chlorambucil / Q000627:therapeutic use*; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D010976:Platelet Count; D013156:Splenectomy
D002699:Chlorambucil; D000493:Allopurinol